From AFR today, CSL CEO Ross Perreault is interviewed in BOSS...

From AFR today, CSL CEO Ross Perreault is interviewed in BOSS magazine:

"On CSL’s pipeline of products – including gene therapies and potentially life-saving second heart attack prevention drugs – clinical trials have restarted with some promising results for CSL112, which has the potential to reduce early recurrent cardiovascular events, and etranacogene dezaparvovec, a gene therapy that could give haemophilia B patients years of functional levels of a blood-clotting protein to prevent bleeding.”EtranaDez isthe first real gene therapy in haemophilia B to be launched and the results look really good,” he says. “But the regulators will be really cautious because they haven’t had a product like this on the market before.”